POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. As of December 27, 2023, POINT Biopharma Global Inc. operates as a subsidiary of Eli Lilly and Company.
Frequently asked questions
What sector does POINT Biopharma Global Inc (PNT) operate in?
POINT Biopharma Global Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is POINT Biopharma Global Inc (PNT) Earnings Per Share (EPS)?
The trailing EPS is $1.10, and the forward EPS is -$0.84.
What is POINT Biopharma Global Inc (PNT) EBITDA?
POINT Biopharma Global Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -34.49 million.
Does POINT Biopharma Global Inc (PNT) pay dividends?
No. POINT Biopharma Global Inc does not pay a dividend.
How did POINT Biopharma Global Inc (PNT) perform in its most recent earnings report?
In the last report (September 30, 2023), POINT Biopharma Global Inc posted an EPS surprise of 23.33% and a revenue surprise of 213.48%.
When is POINT Biopharma Global Inc (PNT) next earnings report?
POINT Biopharma Global Inc is expected to release its next earnings report on December 31, 2023.
